Kura Oncology Inc EHA Investor Event Transcript
Good day, everyone. My name is Stefan and I'll be your conference operator today.
At this time, I'd like to welcome you to Cura Oncology's Investor Call to discuss the long-term results of zistamenib and 7+3 in newly diagnosed AML.
All lines have been placed on mute to prevent any background noise.
After the speaker's remarks, there'll be a question-and-answer session. If you would like to ask a question during this time, and if you've joined via the webinar, please use the raised hand icon, which can be found at the bottom of your webinar application.
To allow everyone the opportunity to participate, we ask that you please limit yourself to one question and one follow-up question, if time permits, at the end of the Q&A session. We'll invite you to rejoin the queue for additional questions. At this time, I'd like to turn the call over to Troy Wilson, President and Chief Executive Officer of Kura Oncology. Please go ahead, Dr. Wilson.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
